A Study of Parsaclisib, a PI3KÎ´ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.
Mantle Cell Lymphoma
DRUG: parsaclisib|DRUG: rituximab|DRUG: bendamustine|DRUG: Placebo
Progression Free Survival, Defined as the time from the date of randomization until the date of first-documented disease progression, as determined by an Independent Review Committee (IRC) based on the Lugano criteria, or death from any cause, whichever happens first., 7 years
Overall Survival, Defined as the time from the date of randomization until death from any cause., 10 years|Objective Response Rate, Defined as the proportion of participants with a Complete Response (CR) or Partial Response (PR) as determined by an IRC- provided radiographic disease assessment of response according to response criteria for lymphomas., 7 Years|Complete Response Rate, Defined as the proportion of participants with a CR as determined by an IRC- provided radiographic disease assessment of response according to response criteria for lymphomas., 7 Years|Duration of Response, Defined as the time from first-documented evidence of CR or PR until first documented disease progression or death from any cause, whichever happens first, among participants who achieve an objective response, as determined by radiographic disease assessment provided by an IRC., 7 Years|Duration Of Complete Response, Defined as the time from the first evidence of CR to the date of first documented disease progression or death from any cause, whichever happens first, among participants who achieve a CR, as determined by radiographic disease assessment provided by an IRC., 7 Years|Disease Control Rate, Defined as the proportion of participants who achieved a response of CR, PR, or Stable Disease (SD) assessed by an IRC., 7 Years|Event Free Survival, Defined as the time from date of randomization to date of first documented progression, as determined by radiographic disease assessment provided by an IRC, administration of a new anti lymphoma treatment, or death from any cause, whichever happens first., 7 Years|Time To Next anti-Lymphoma Treatment, Defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment., 7 Years|Progression-Free Survival on next anti-lymphoma treatment, Defined as the time from the date of randomization to the date of first documented disease progression as reported by investigator after next anti-lymphoma treatment or death from any cause, or start of a third anti-lymphoma treatment since randomization, whichever happens first., 7 Years|Treatment Emergent Adverse Events, Adverse events reported for the first time or worsening of a pre-existing event after the first dose of study drug/treatment., 7 Years
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.